High Macular Fluid volume risk factor for progressive neovascular age-related macular degeneration

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-18 17:30 GMT   |   Update On 2023-12-19 08:55 GMT

High Macular Fluid volume risk factor for progressive neovascular age-related macular degeneration suggests a new study published in the Canadian Journal of Ophthalmology.A study was done to investigate the effect of macular fluid volumes (subretinal fluid [SRF], intraretinal fluid [IRF], and pigment epithelium detachment [PED]) after initial treatment on functional and structural outcomes...

Login or Register to read the full article

High Macular Fluid volume risk factor for progressive neovascular age-related macular degeneration suggests a new study published in the Canadian Journal of Ophthalmology.

A study was done to investigate the effect of macular fluid volumes (subretinal fluid [SRF], intraretinal fluid [IRF], and pigment epithelium detachment [PED]) after initial treatment on functional and structural outcomes in neovascular age-related macular degeneration in a real-world cohort from Fight Retinal Blindness!

Treatment-naive neovascular age-related macular degeneration patients from Fight Retinal Blindness! (Zürich, Switzerland) were included. Macular fluid on optical coherence tomography was automatically quantified using an approved artificial intelligence algorithm. Follow-up of macular fluid, number of anti-vascular endothelial growth factor treatments, effect of fluid volumes after initial treatment (high, top 25%; low, bottom 75%) on best-corrected visual acuity, and development of macular atrophy and fibrosis was investigated over 48 months.

Results

A total of 209 eyes (mean age, 78.3 years) were included. Patients with high IRF volumes after initial treatment differed by –2.6 (p = 0.021) and –7.4 letters (p = 0.007) at months 12 and 48, respectively. Eyes with high IRF received significantly more treatments (+1.6 [p < 0.001] and +5.3 [p = 0.002] at months 12 and 48, respectively). Patients with high SRF or PED had comparable best-corrected visual acuity outcomes but received significantly more treatments for SRF (+2.4 [p < 0.001] and +11.4 [p < 0.001] at months 12 and 48, respectively) and PED (+1.2 [p = 0.001] and +7.8 [p < 0.001] at months 12 and 48, respectively).

Patients with high macular fluid after initial treatment are at risk of losing vision that may not be compensable with higher treatment frequency for IRF. Higher treatment frequency for SRF and PED may result in comparable treatment outcomes. Quantification of macular fluid in all compartments is essential to detect eyes at risk of aggressive disease.

Reference:

Long-term effect of fluid volumes during the maintenance phase in neovascular age-related macular degeneration: results from Fight Retinal Blindness. Gregor S. Reiter, Virginia Mares Oliver Leingang, Hrvoje Bogunovic, Daniel Barthelmes, Ursula Schmidt-Erfurth

Open AccessPublished:November 18, 2023DOI:https://doi.org/10.1016/j.jcjo.2023.10.017

Keywords:

Long-term, effect, fluid, volumes, during, maintenance, phase, neovascular, age-related, macular, degeneration, results, Fight, Retinal, Blindness, Gregor S. Reiter, Virginia Mares Oliver Leingang, Hrvoje Bogunovic, Daniel Barthelmes, Ursula Schmidt-Erfurth, Canadian Journal of Ophthalmology

Tags:    
Article Source : Canadian Journal of Ophthalmology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News